A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
about
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activitySynthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 InhibitorsScaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentMolecular docking and ligand specificity in fragment-based inhibitor discoveryLeveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomalleiStructural characterization and inhibition of the Plasmodium Atg8–Atg3 interactionDesign and pharmacology of a highly specific dual FMS and KIT kinase inhibitorDiscovery of triazines as selective PDE4B versus PDE4D inhibitorsFragment approaches in structure-based drug discoveryNovel inhibitors of anthrax edema factor.New classes of PDE7 inhibitors identified by a fission yeast-based HTS.Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.Fragment screening of infectious disease targets in a structural genomics environmentDesign of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics.A fission yeast-based platform for phosphodiesterase inhibitor HTSs and analyses of phosphodiesterase activity.The benefits of constructing leads from fragment hits.Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies.Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge.Advances in targeting cyclic nucleotide phosphodiesterasescGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Advances in fragment-based drug discovery platforms.Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.Saturation transfer difference NMR for fragment screening.Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification.Structural proteomics in drug discovery.Biofocussed chemoprospecting: An efficient approach for drug discovery.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.Calcium-channel modulators for cardiovascular disease.New approaches to molecular cancer therapeutics.A decade of fragment-based drug design: strategic advances and lessons learned.Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesteraseVasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission.Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics.Computational medicinal chemistry in fragment-based drug discovery: what, how and when.Fragment informatics and computational fragment-based drug design: an overview and update.When analoging is not enough: scaffold discovery in medicinal chemistry.Targeting enzyme inhibitors in drug discovery.(E)-3,5-Dimethyl-1-p-tolyl-4-(p-tolyl-diazen-yl)-1H-pyrazole.Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction.
P2860
Q24307789-62E24F0A-62F5-44FC-9C89-41635344DB41Q24652600-11F1D3D8-F0CC-4B20-A388-1B559F8E7B16Q27322207-94B067EE-7F05-4C21-ABD4-9FC5F56677A0Q27653305-23967657-1493-4D8F-9D29-AF6636123212Q27654237-5F3E7BF3-2111-490E-BFCB-FA0A603306D6Q27667103-DC236C0A-9166-4855-B348-F339E118F9CCQ27673186-0366F94C-4BDE-4DC0-9AB7-2B037B0E37E5Q27676827-4A7E6E90-7F36-43D7-9904-7D62B5CF01E8Q27684573-DB87FE93-A448-4B2A-BCBA-73E88B7D6C0CQ33329074-512526EB-7D41-442E-99B8-ED573EBDDF95Q33351165-4BF82EE5-A3EB-47C6-9205-3FA78D90A038Q33540646-2175BED1-7BB7-4549-BADE-A8071B16ACDCQ33684605-A00CFF0A-AF98-4FDB-93C8-0388E7A2C84AQ33836468-4AF7E37F-33F8-46A6-B1FF-7D92EFDC83EFQ33908733-95DFFB73-862F-4CFF-B796-2A0A689DB4CEQ33939889-80142665-1C76-4AF6-92D0-DD81D0143D73Q33977454-FDB6F92F-55DB-4F55-B273-D2E362FAC9A7Q34070346-5E6FFEDA-390F-4BD3-8A5F-4413C8718689Q34127928-7E073E04-9585-4693-B7A9-F60CA2420FF9Q34139490-4E7341B1-B20B-4234-913D-83E233E2959FQ34244951-51A83441-CACB-4DFE-BB81-D265CCDFC7BAQ34616682-6D496E9C-A9B1-487B-A36E-976CAC8CB2ECQ34765802-AF23A7B1-2ABB-4B32-A580-471E6E912B71Q35082073-DA104FA8-6925-4914-B1B9-EC7B2C7D3964Q35092268-51B12A50-C442-4CCA-B5D7-00BED85DB9E5Q36227936-D1AAFBB8-0D37-4D6A-AF76-92E8F703AAE4Q36264598-4F03357B-D842-40C8-8A5E-87F4740352B6Q36334968-BD326207-416B-4FA7-84DE-5A407202AD30Q36407405-78410E60-1B52-4F77-9EA6-3DC29100FFD3Q36654909-7EDF57F8-C9AE-4875-A8B4-503B47065CD3Q36732253-C951A578-D252-4545-B15C-D9CE77DC7D5FQ36855547-BEB35C39-C415-41A7-BDED-D546B1B91F04Q37329329-B78E2F7D-CF9B-4C4A-83AF-AE38952611E8Q37391836-6B88DA0A-FFBC-4B15-8985-FBF253EC2E64Q37856296-8A990DFA-AA02-492A-85AF-1BF6FB321970Q37995087-64A3AA05-0A6C-4A73-98BB-D75475E89D81Q38028518-A43EE415-74B6-48F7-BA21-6EE7193D62B3Q40197049-C1DEA0BD-00E9-42BE-BB34-571032887D0AQ40937866-AAF7F7DA-0B7F-4ACB-8ADF-A1E5793CEFE5Q42515895-A1C62410-365D-4645-B41B-E840874EA85B
P2860
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
A family of phosphodiesterase ...... nd scaffold-based drug design.
@ast
A family of phosphodiesterase ...... nd scaffold-based drug design.
@en
type
label
A family of phosphodiesterase ...... nd scaffold-based drug design.
@ast
A family of phosphodiesterase ...... nd scaffold-based drug design.
@en
prefLabel
A family of phosphodiesterase ...... nd scaffold-based drug design.
@ast
A family of phosphodiesterase ...... nd scaffold-based drug design.
@en
P2093
P2860
P50
P356
P1433
P1476
A family of phosphodiesterase ...... nd scaffold-based drug design.
@en
P2093
Bruce P England
Daniel Fong
Dean R Artis
Graeme L Card
Kam Y J Zhang
Landy Blasdel
Michael V Milburn
Prabha N Ibrahim
Sam Gillette
Yoshihisa Suzuki
P2860
P2888
P304
P356
10.1038/NBT1059
P577
2005-01-30T00:00:00Z
P5875
P6179
1052543566